Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Identification of early neurodegenerative pathways in progressive multiple sclerosis.

Kaufmann M. et al, (2022), Nat Neurosci

Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS).

Dobson R. et al, (2022), Mult Scler Relat Disord, 63

Out with the old, in with the new: Could plasma exchange be used to fill a therapeutic gap in neurology?

Spencer JI. et al, (2021), J Neurol Sci

Contemporary Neuroscience Core Curriculum for Medical Schools.

Gelb DJ. et al, (2021), Neurology

Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.

Sadovnick AD. et al, (2021), Mult Scler

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.

Yeo T. et al, (2021), Brain Commun, 3

Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships.

Geraldes R. et al, (2020), Brain, 143, 2998 - 3012

Leading with inclusion during the COVID-19 pandemic: Stronger together.

Warrior L. et al, (2020), Neurology, 95, 537 - 542

The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.

Geraldes R. et al, (2020), Mult Scler

The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.

Geraldes R. et al, (2020), Mult Scler

A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application.

Yeo T. et al, (2020), Sci Rep, 10

Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.

Geraldes R. et al, (2020), J Neurol Neurosurg Psychiatry

Approach to the patient with neurologic disease

DE LUCA G. and Griggs R., (2019), Goldman-Cecil Medicine, 2-Volume Set

Sir Hugh Cairns: a pioneering collaborator.

Attwood JE. et al, (2019), Acta Neurochir (Wien)

A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.

Coe S. et al, (2019), J Neurol Neurosurg Psychiatry, 90, 507 - 513

Multiple sclerosis and the risk of systemic venous thrombosis: A systematic review.

Ahmed O. et al, (2019), Mult Scler Relat Disord, 27, 424 - 430

Rapamycin in ischemic stroke: Old drug, new tricks?

Hadley G. et al, (2018), J Cereb Blood Flow Metab

From Nose to Gut - The Role of the Microbiome in Neurological Disease.

Bell JS. et al, (2018), Neuropathol Appl Neurobiol

Genes, smoking, and organic solvent exposure: An alarming cocktail for MS risk.

Bell JS. and DeLuca GC., (2018), Neurology, 91, 199 - 200

Comparing and Contrasting the Approach to Advance Care Planning in Multiple Sclerosis

DE LUCA G. and Hutchinson J., (2018), Case Studies in Neuropalliative Care

Load More

1
2
3
4
5
6

Include forthcoming?